



November 07, 2012

The Secretary
Bangalore Stock Exchange Ltd.
Stock Exchange Tower
51, 1st Cross, J C Road
Bangalore 560 027

Dear Sirs

Sub: Un-audited Financial Results of the Company / Limited Review Report
Ref: Clause 41 of Listing Agreement

Scrip Code – Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ

Pursuant to Clause 41 of the Listing Agreement, please find attached the Un-audited Financial Results for the second quarter and half year ended September 30, 2012, which have been approved by the Board of Directors of the Company at its meeting held today, November 07, 2012.

The Limited Review Report dated November 07, 2012 issued by the Statutory Auditors in respect of the aforesaid Unaudited Financial Results is also attached.

Kindly take the same on record.

Thanking You,

For **AstraZeneca Pharma India Limited**


Pawan Singh
Vice President - Legal & Company Secretary

CC : **Bombay Stock Exchange Limited**
Corporate Relationship Dept., P J Towers, Dalal Street, Fort, Mumbai 400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051

AstraZeneca Pharma India Limited
Regd. Office 'Aviskar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial results for the quarter and six months ended 30 September 2012

Part I		Rs in lakhs (except for number of shares)					
Sl No.	Particulars	3 months ended 30/09/2012	3 months ended 30/06/2012	3 months ended 30/09/2011	6 months ended 30/09/2012	6 months ended 30/09/2011	Previous year ended 31/03/2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net sales/ income from operations (net of excise duty)	9,922.82	9,126.08	14,862.43	19,048.90	28,610.66	53,127.97
	b) Other operating income	4.88	2.79	4.43	7.67	10.47	24.05
	Total income from operations (net)	9,927.70	9,128.87	14,866.86	19,056.57	28,621.13	53,152.02
2	Expenses						
	(a) Cost of materials consumed	1,379.29	715.85	1,993.81	2,095.14	4,392.90	7,151.68
	(b) Purchase of stock-in-trade	2,429.15	2,623.54	2,620.13	5,052.69	5,768.57	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	563.69	452.24	(93.05)	1,015.93	(1,484.67)	(1,210.38)
	(d) Employee benefits expense	3,859.01	3,339.55	3,523.44	7,198.56	6,877.06	16,191.24
	(e) Depreciation and amortisation expense	250.31	175.14	191.28	425.45	364.02	733.86
	(f) Other expenses	3,701.78	3,924.42	3,639.80	7,626.20	7,367.26	16,070.05
	Total expenses	12,183.23	11,230.74	11,875.41	23,413.97	23,285.14	50,859.58
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(2,255.53)	(2,101.87)	2,991.45	(4,357.40)	5,335.99	2,292.44
4	Other income	173.92	783.53	140.96	957.45	285.19	633.04
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(2,081.61)	(1,318.34)	3,132.41	(3,399.95)	5,621.18	2,925.48
6	Finance costs	-	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(2,081.61)	(1,318.34)	3,132.41	(3,399.95)	5,621.18	2,925.48
8	Exceptional items	-	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(2,081.61)	(1,318.34)	3,132.41	(3,399.95)	5,621.18	2,925.48
10	Tax expense (Refer note 6)	2,429.97	(503.74)	1,024.01	1,926.23	1,837.96	948.97
11	Net profit/(loss) from ordinary activities after tax (9-10)	(4,511.58)	(814.60)	2,108.40	(5,326.18)	3,783.22	1,976.51
12	Extraordinary Item	-	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(4,511.58)	(814.60)	2,108.40	(5,326.18)	3,783.22	1,976.51
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	-	-	-	-	-	18,428.52
16	Basic and diluted earnings (Rs) per share (not annualised)	(18.05)	(3.26)	8.43	(21.30)	15.13	7.91

Part II							
A	Particulars of shareholding						
1	Public shareholding						
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

B.	Particulars	3 months ended 30/09/2012
	Investor complaints	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	10
	Disposed of during the quarter	10
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 7 November 2012.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Other income for the quarter ended 30 June 2012 and the period ended 30 September 2012 includes an amount of Rs 693.49 lakhs towards compensation for factory land acquired by National Highway Authority of India in the previous year.
- At the end of the previous financial year, the factory experienced interruptions to the supply of certain products. While several products have been returned to the market, the Company continues to pursue a remediation plan to address these interruptions. As a result of these interruptions, revenues and the financial results for the current quarter and the half year ended 30 September 2012 are lower compared to the prior period.
- In view of the inadequacy of profit during the current half year, the remuneration paid to the Managing Director up to 31 August 2012 (date of his resignation) and that paid/ payable to the Whole Time Director is subject to compliance with the requirements of Schedule XIII to the Companies Act, 1956.
- Tax expense represents deferred tax assets amounting to Rs 2,429.97 lacs which have been charged to the profit and loss for the quarter ended 30 September 2012.
- The above statement of financial results have been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Bangalore
Dated: 7 November 2012

Ruby Lau
Whole Time Director



7/11/12.

AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl.no.	Particulars	3 months ended 30/09/2012 (Unaudited)	3 months ended 30/06/2012 (Unaudited)	3 months ended 30/09/2011 (Unaudited)	6 months ended 30/09/2012 (Unaudited)	6 months ended 30/09/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	Segment revenue						
	(a) Healthcare	9,259.78	8,327.42	14,205.80	17,587.20	27,153.66	49,977.92
	(b) Others	667.92	801.45	661.06	1,469.37	1,467.47	3,174.10
	Total	9,927.70	9,128.87	14,866.86	19,056.57	28,621.13	53,152.02
	Less: Inter-segment revenue	-	-	-	-	-	-
	Net income from operations	9,927.70	9,128.87	14,866.86	19,056.57	28,621.13	53,152.02
2	Segment results						
	Profit/(loss) before tax and interest						
	(a) Healthcare	(2,306.31)	(2,078.25)	2,923.52	(4,384.56)	5,240.58	2,165.28
	(b) Others	50.78	(23.62)	67.93	27.16	95.41	127.16
	Total	(2,255.53)	(2,101.87)	2,991.45	(4,357.40)	5,335.99	2,292.44
	Add: Other income	173.92	783.53	140.96	957.45	285.19	633.04
	Less: Interest	-	-	-	-	-	-
	Total profit/(loss) before tax	(2,081.61)	(1,318.34)	3,132.41	(3,399.95)	5,621.18	2,925.48
3	Capital employed						
	(a) Healthcare	9,279.12	13,056.25	14,973.36	9,279.12	14,973.36	11,722.25
	(b) Others	454.42	619.21	463.97	454.42	463.97	817.67
	(c) Unallocated	3,868.80	4,438.47	6,314.85	3,868.80	6,314.85	6,388.60
	Total	13,602.34	18,113.93	21,752.18	13,602.34	21,752.18	18,928.52

Notes:

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.



AstraZeneca Pharma India Limited
Regd Office : "Avishkar" Off Bellary Road , Hebbal Bangalore - 560 024
Statement of assets and liabilities

(Rs in lakhs)

Sl.no.	Particulars	As at	As at
		30 September 2012	31 March 2012
		(Unaudited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	13,102.34	18,428.52
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	13,602.34	18,928.52
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	48.44	54.44
	(d) Long-term provisions	-	-
	Sub-total - Non-current liabilities	48.44	54.44
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	5,988.32	1,776.54
	(c) Other current liabilities	8,187.62	8,619.33
	(d) Short-term provisions	2,274.84	4,829.60
	Sub-total - Current liabilities	16,450.78	15,225.47
	TOTAL - EQUITY AND LIABILITIES	30,101.56	34,208.43
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	9,498.54	9,018.24
	(b) Non-current investments	0.57	0.57
	(c) Deferred tax assets (net)	-	1,776.23
	(d) Long-term loans and advances	2,969.14	3,460.40
	(e) Other non-current assets	196.92	196.92
	Sub-total - Non-current assets	12,665.17	14,452.36
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	6,576.27	7,509.69
	(c) Trade receivables	4,171.50	3,230.79
	(d) Cash and bank balances	2,946.71	5,365.07
	(e) Short-term loans and advances	2,069.68	2,415.95
	(f) Other current assets	1,672.23	1,234.57
	Sub-total - Current assets	17,436.39	19,756.07
	TOTAL - ASSETS	30,101.56	34,208.43



7/11/12.

B S R & Co.

(Registered)
Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 3980 6000
Fax +91 80 3980 6999

Review report to the Board of Directors of AstraZeneca Pharma India Limited

We have reviewed the accompanying statement of unaudited financial results of AstraZeneca Pharma India Limited ("the Company") for the quarter and half year ended 30 September 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results for the quarter and half year ended 30 September 2012, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co.**
Chartered Accountants
Firm Registration Number: 101248W



Zubin Shekary
Partner
Membership Number: 48814

Place: Bangalore
Date: 7 November 2012